SenesTech (SNES) AI Stock Analysis

• Market Cap: $9.59M
• Dividend Yield: N/A
• Average Volume (3M): 66.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: 39.37%
• EPS Growth: 69.81%
• Country: US
• Employees: 23
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.28
• Shares Outstanding: 5,185,333
• 10 Day Avg. Volume: 49,700
• 30 Day Avg. Volume: 66,031
• PEG Ratio: <0.01
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 1.24
• P/FCF Ratio: -0.38
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 2.61
• Enterprise Value/Gross Profit: 4.11
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $10.00
• Price Target Upside: 292.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $2.00 ▼(-21.57% Downside)

The score is held down primarily by weak financial fundamentals (ongoing losses and negative cash flow) and bearish technical positioning (below key moving averages with negative MACD). The earnings call provides a meaningful offset due to strong revenue growth and improving cost discipline, but valuation remains constrained by negative earnings and the lack of a dividend.

Positive Factors

Revenue Growth & Product Adoption

A 43% YoY revenue increase driven by the Evolve product indicates durable product-market fit and accelerating commercial traction. Sustained adoption reduces go-to-market risk, broadens the customer base beyond legacy offerings, and supports scalable revenue growth as distribution channels mature over quarters.

High Gross Margins

Consistently ~63% gross margins signal favorable unit economics and pricing power for SenesTech’s products. High gross margins provide structural capacity to cover SG&A and R&D, improving the odds of reaching profitability as top-line growth continues and operating expenses are compressed or optimized.

Improving Liquidity Runway

A cash balance north of $10M gives the company runway to fund expansion, municipal deployments and e-commerce scaling without immediate capital raises. This liquidity reduces short-term financing pressure and supports execution on growth initiatives while management works toward sustained profitability.

Negative Factors

Negative Cash Flow & Ongoing Losses

Persistent negative operating and free cash flows demonstrate structural unprofitability despite revenue gains. Continued cash burn limits flexibility to invest in sales, approvals, or supply chain, raising the probability of future financing, dilution, or painful cost cuts that could impede long-term growth.

Decline in Legacy ContraPest Sales

A ~31% YoY drop in ContraPest revenues highlights product-mix risk and erosion of a legacy revenue stream. If growth from Evolve or other channels slows, the company may face net revenue pressure, reducing predictability and making it harder to sustain fixed costs and fund expansion without offsetting gains.

Executive Leadership Transition Risk

Announcement of the CEO’s pending retirement and appointment of an interim executive chair creates strategic and execution uncertainty during a scaling phase. Leadership turnover can delay critical decisions, disrupt partner and municipal relationships, and increase execution risk for commercialization and international approvals over months.

SenesTech Business Overview & Revenue Model

Company Description

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

How the Company Makes Money

SenesTech generates revenue primarily through the sale of its flagship product, ContraPest, to various sectors including agriculture, municipalities, and commercial pest control operators. The company has established key partnerships with pest control companies and agricultural firms that help in distributing its product. Additionally, SenesTech may derive income from licensing agreements and potential collaborations with other biotech firms or research institutions aimed at expanding its product offerings and technology applications. The company's revenue model is centered around product sales, with a focus on building long-term relationships with clients to ensure repeat business.

SenesTech Financial Statement Overview

Summary

Revenue is growing, but profitability remains weak with negative net income and negative margins. Cash flow is also pressured with negative operating and free cash flow, partially offset by manageable leverage (moderate debt-to-equity).

Income Statement

SenesTech has shown some revenue growth, with a 9.94% increase in the TTM period. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is relatively healthy at 64.12%, but the consistent negative net income suggests ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.39, indicating a manageable level of debt relative to equity. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is not provided, but the overall leverage appears to be under control.

Cash Flow

SenesTech's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is somewhat aligned with net income, albeit both are negative. The company has not shown consistent improvement in free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.30M	1.86M	1.19M	1.02M	576.00K	258.00K
Gross Profit	1.46M	1.00M	539.00K	464.00K	220.00K	-23.00K
EBITDA	-5.67M	-6.01M	-7.57M	-9.51M	-7.95M	-7.62M
Net Income	-5.83M	-6.18M	-7.71M	-9.70M	-8.27M	-7.94M
Balance Sheet
Total Assets	14.62M	3.28M	7.29M	6.78M	11.50M	6.02M
Cash, Cash Equivalents and Short-Term Investments	10.25M	1.31M	5.39M	4.78M	9.33M	3.64M
Total Debt	2.68M	262.00K	406.00K	359.00K	555.00K	1.44M
Total Liabilities	3.28M	767.00K	942.00K	1.50M	1.47M	2.14M
Stockholders Equity	11.35M	2.51M	6.35M	5.28M	10.04M	3.88M
Cash Flow
Free Cash Flow	-5.44M	-6.12M	-7.71M	-8.75M	-7.88M	-7.22M
Operating Cash Flow	-5.30M	-6.03M	-7.57M	-8.58M	-7.78M	-7.11M
Investing Cash Flow	-3.10M	-56.00K	-149.00K	-170.00K	-99.00K	-67.00K
Financing Cash Flow	13.17M	2.00M	8.34M	4.20M	13.56M	8.88M

SenesTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Negative. The current price of 2.55 is above the 20-day moving average (MA) of 2.07, above the 50-day MA of 2.36, and below the 200-day MA of 3.52, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 42.40 is Neutral, neither overbought nor oversold. The STOCH value of 49.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNES.

SenesTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
FSI	61 Neutral	$73.24M	40.44	5.08%	―	0.18%	-54.25%
NTIC	57 Neutral	$86.00M	-261.13	0.02%	1.33%	-0.97%	-99.67%
LOOP	48 Neutral	$58.49M	-22.10	―	―	11013.00%	39.85%
SNES	47 Neutral	$9.59M	-0.56	-77.79%	―	39.37%	69.81%
GURE	43 Neutral	$6.16M	-0.09	-43.37%	―	61.85%	49.02%

SenesTech Corporate Events

SenesTech Announces CEO Retirement and Interim Leadership Transition

On January 22, 2026, SenesTech announced that President and CEO Joel L. Fruendt plans to retire from the company and its board by the earlier of June 30, 2026 or the appointment of a new chief executive, under a separation agreement that provides salary continuation through mid-December 2026, health insurance coverage through the end of 2026, and accelerated vesting of his stock options. On January 26, 2026, the board named director Jamie Bechtel as Interim Executive Chair with an annual compensation of $247,500 for this role, signaling an orderly leadership transition designed to provide governance continuity while the company searches for Fruendt’s successor, with potential implications for strategic direction and stakeholder confidence during the changeover period.

The most recent analyst rating on (SNES) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.

SenesTech Appoints Michael Edell as Interim COO

On November 7, 2025, SenesTech announced the appointment of Michael Edell as the Interim Chief Operating Officer, effective November 3, 2025. Under the terms of the employment agreement, Mr. Edell will receive a monthly salary of $30,000 and potential bonuses for Q4 2025 and Q1 2026, but will not be eligible for company-sponsored benefits. The agreement is for six months, with a 60-day notice period required for termination without cause.

The most recent analyst rating on (SNES) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.